Blog
RSS FeedPosted by Michael Wonder on 15 Mar 2018
Agenda for 21 March TC meeting
15 March 2018 - HAS has posted the agenda for the next scheduled TC meeting. ...
Posted by Michael Wonder on 15 Mar 2018
Pharmacare and the chaotic world of Canadian drug prices
15 March 2018 - The cost of a life-saving drug to treat cystinosis — a rare disease affecting probably 100 ...
Posted by Michael Wonder on 15 Mar 2018
NICE Medtech Early Technical Assessment tool to form part of government grant application process for health care product developers
15 March 2018 - The Medtech Early Technical Assessment (META) tool has been selected , as an option, to form part ...
Posted by Michael Wonder on 15 Mar 2018
Decision to open list montelukast tablets
15 March 2018 - PHARMAC will remove the Special Authority and Hospital Medicine restrictions on montelukast 4 mg, 5 mg ...
Posted by Michael Wonder on 15 Mar 2018
PHARMAC publishes indicative agenda for May 2018 PTAC meeting
15 March 2018 - The May 2018 PTAC meeting will review the following applications for several new medicines. ...
Posted by Michael Wonder on 14 Mar 2018
Breast cancer drug approved for NHS use
13 March 2018 - The use of new drugs to treat breast cancer and Hodgkin’s lymphoma has been approved, bringing Scottish ...
Posted by Michael Wonder on 13 Mar 2018
Price and clinical factors impact Canadian orphan drug recommendation rates
11 March 2018 - Canada’s Common Drug Review (CDR), which provides recommendations on public payer reimbursement for all non-oncology drugs, ...
Posted by Michael Wonder on 13 Mar 2018
Canadian families stunned by 3,000% increase in price of life-saving drug
12 March 2018 - Drug for patients with cystinosis being replaced by new form with same active ingredient. ...
Posted by Michael Wonder on 13 Mar 2018
Cutting-edge NHS drugs do more harm than good
12 March 2018 - Almost all new drugs approved for NHS use do more harm than good, according to modelling ...
Posted by Michael Wonder on 13 Mar 2018
Analysis: new drug decisions and NHS spending conundrums
12 March 2018 - The latest round of drug decisions from the Scottish Medicines Consortium throws up the usual mix ...
Posted by Michael Wonder on 13 Mar 2018
SMC - March 2018 decisions
12 March 2018 - SMC accepts new medicines for breast cancer and Hodgkin’s lymphoma for use by NHSScotland ...
Posted by Michael Wonder on 12 Mar 2018
NICE minded to reject Keytruda for classical Hodgkin lymphoma
12 March 2018 - Cost regulators for NHS therapies in England and Wales say they are minded not to recommend ...
Posted by Michael Wonder on 11 Mar 2018
Proposal to widen access and change the funded brand of tenofovir disoproxil and entecavir
9 March 2018 - PHARMAC is delighted to propose the widening of access to tenofovir disoproxil and entecavir, anti-viral medicines ...
Posted by Michael Wonder on 11 Mar 2018
The relative importance of clinical, economic, patient values and feasibility criteria in cancer drug reimbursement in Canada: a revealed preferences analysis of recommendations of the pan-Canadian Oncology Drug Review 2011–2017
20 January 2018 - Most Canadian provinces and territories rely on the pan-Canadian Oncology Drug Review to provide recommendations regarding public ...
Posted by Michael Wonder on 08 Mar 2018
CADTH Common Drug Review will accept submissions up to six months pre-Notice of Compliance
8 March 2018 - Operational change can help reduce the time between regulatory approval and reimbursement recommendations for prescription drugs ...